台灣臨床試驗主持人資料庫|TPIDB

2018-03-01 - 2021-03-31

Phase III

Completed

A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation

Condition/Disease

Schizophrenia
Test Drug

Paliperidone Palmitate

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

楊延光

National Taiwan University Hospital

Division of Psychiatry

白雅美

Taipei Veterans General Hospital

Division of Psychiatry

2019-03-28 - 2029-04-06

Phase III

Active

An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS)

Condition/Disease

Relapsing Multiple Sclerosis
Test Drug

OMB157

Participate Sites
1Sites

Terminated1Sites

林宙晴

National Taiwan University Hospital

Division of Neurology

2017-05-16 - 2019-09-30

Phase I

Completed

Phase 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia

Condition/Disease

Acute Myeloid Leukemia
Test Drug

ADI-PEG 20

Participate Sites
3Sites

Terminated3Sites

陳彩雲

National Taiwan University Hospital

Division of General Internal Medicine

2013-02-15 - 2018-09-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Condition/Disease

Acute Coronary Syndrome
Test Drug

SAR236553/REGN727

Participate Sites
15Sites

Terminated15Sites

蔡惟全

National Taiwan University Hospital

Division of Cardiovascular Diseases

2019-02-01 - 2020-12-31

Phase I

A Phase 1, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetic and efficacy of NBM-BMX in subjects with advanced solid tumors

Condition/Disease

Malignant Neoplasm
Test Drug

NBM-BMX

Participate Sites
2Sites

Recruiting2Sites

葉裕民

National Taiwan University Hospital

Division of Hematology & Oncology

顏厥全

Taipei Veterans General Hospital

Division of Hematology & Oncology

2011-07-01 - 2015-07-31

Phase III

A Randomized, Double-Blind, Parallel, Vehicle-Controlled Phase III Trail to Assess the Efficacy and Safety of Topical SR-T100 Gel in the Treatment of Patients with Actinic Keratosis

Condition/Disease

Actinic Keratosis
Test Drug

SR-T100

Participate Sites
6Sites

Terminated6Sites

王德華

National Taiwan University Hospital

Division of Dermatology

2017-08-01 - 2020-05-31

Phase III

Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes PRONTO-T1D.

Condition/Disease

Type 1 Diabetes Mellitus
Test Drug

LY900014

Participate Sites
6Sites

Terminated6Sites

歐弘毅

National Taiwan University Hospital

Division of Endocrinology

2017-09-21 - 2020-12-31

Phase III

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Condition/Disease

Advanced Breast Cancer
Test Drug

Ribociclib (LEE011)/ Letrozole/Goserelin

Participate Sites
6Sites

Terminated5Sites

鍾為邦

National Taiwan University Hospital

Division of Hematology & Oncology

邱昌芳

China Medical University Hospital-Taipei

未分科

2013-08-01 - 2017-12-31

Phase III

A Randomized, Double-blind, Parallel Group Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride (0.5mg) and Tamsulosin (0.2mg) With Tamsulosin (0.2mg) Monotherapy, Administered Once Daily for 2 Years, on the Improvement of Symptoms and Health Outcomes in Men With Moderate to Severe Benign Prostatic Hyperplasia

Condition/Disease

Moderate to Severe Benign Prostatic Hyperplasia
Test Drug

(1) AVODART SOFT CAPSULES；(2) Harnalidge D tablets

Participate Sites
8Sites

Not yet recruiting1Sites

Terminated7Sites

鄭鴻琳

National Taiwan University Hospital

Division of Urology

2015-03-01 - 2016-10-26

Phase II

A Phase 2, Multicenter, Randomized, Open-label, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Treatment naïve East Asian Subjects With Chronic Hepatitis C Virus Genotype 1b Infection.

Condition/Disease

Hepatitis C
Test Drug

TG-2349

Participate Sites
9Sites

Terminated9Sites

鄭斌男

National Taiwan University Hospital

Division of General Internal Medicine

Search Result

List